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Abstract
Aims/hypothesis The aim of the present study was to
estimate the heritability of the beta cell insulin response to
glucose and to glucose combined with glucagon-like
peptide-1 (GLP-1) or with GLP-1 plus arginine.
Methods This was a twin-family study that included 54
families from the Netherlands Twin Register. The partici-
pants were healthy twin pairs and their siblings of the same
sex, aged 20 to 50 years. Insulin response of the beta cell
was assessed by a modified hyperglycaemic clamp with
additional GLP-1 and arginine. Insulin sensitivity index
(ISI) was assessed by the euglycaemic–hyperinsulinaemic
clamp. Multivariate structural equation modelling was used
to obtain heritabilities and the genetic factors underlying
individual differences in BMI, ISI and secretory responses
of the beta cell.
Results The heritability of insulin levels in response to
glucose was 52% and 77% for the first and second phase,
respectively, 53% in response to glucose+GLP-1 and 80%
in response to an additional arginine bolus. Insulin
responses to the administration of glucose, glucose+GLP-1
and glucose+GLP-1+arginine were highly correlated
(0.62<r<0.79). Heritability of BMI and ISI was 74% and
60% respectively. The genetic factors that influenced BMI
and ISI explained about half of the heritability of insulin
levels in response to the three secretagogues. The other half
was due to genetic factors specific to the beta cell.
Conclusions/interpretation In healthy adults, genetic factors
explain most of the individual differences in the secretory
capacity of the beta cell. These genetic influences are partly
independent from the genes that influence BMI and ISI.
Keywords Arginine . Beta cell . Genes . GLP-1 .
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Abbreviations
A Additive genetic variance
ARG-IR Arginine-induced insulin response
C Common environmental variance shared by
family members
E Unique environmental variance
GLP-1IR GLP-1 stimulated insulin response
GLP-1 Glucagon-like peptide-1
GWA Genome-wide association
ISI Insulin sensitivity index
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Introduction
Type 2 diabetes mellitus is a multifactorial disease,
characterised by decreased insulin sensitivity and inade-
quate insulin secretion by the pancreatic beta cell [1]. Twin
[2–5] and family studies [6–10] support the notion that
people who develop type 2 diabetes have a strong genetic
predisposition, which may be partly conveyed through
genetic effects on insulin resistance. Two twin studies, for
instance, showed a significant genetic contribution to
insulin sensitivity, assessed by euglycaemic–hyperinsulin-
aemic clamp with heritability estimates of 37% and 55%
[11, 12]. Notwithstanding the importance of insulin
sensitivity, genetic effects on beta cell function are likely
to play a major role in the development of type 2 diabetes.
Thus many of the genetic variants in and near genes
recently found to be associated with risk of type 2 diabetes
[13] influence beta cell function [14]. In twin studies, the
genetic contribution to beta cell function has been tested
mostly by examining surrogate measurements of insulin
secretion derived from fasting blood levels or in response to
oral glucose. In five studies using IVGTT, heritability
estimates of the acute insulin response to glucose ranged
from 35% to 76% [6, 11, 15–17]. The heritability of the
second-phase insulin response to glucose in an IVGTT has
been investigated in two of these studies only [11, 17] and
was estimated to be 28% and 58%.
Glucose is the key regulator of insulin secretion by the
beta cell, which occurs through activation of the glycolytic
flux, followed by mitochondrial activation, membrane
depolarisation and finally release of insulin. However,
under typical physiological conditions various non-glucose
secretagogues also affect insulin secretion. These include
incretins like glucagon-like petide-1 (GLP-1), which is
immediately secreted by the gut in reaction to a meal [18]
and causes G-protein-coupled receptor activation of adeny-
late cyclase, and amino acids like arginine, which depolar-
ises the beta cell membrane [19]. Abnormal insulin
responses after administration of these secretagogues may
be a first sign of development of type 2 diabetes mellitus
[20]. To date, no studies have estimated the heritability of
insulin response to glucose combined with GLP-1 and
arginine. Furthermore, it is unclear whether the secretory
responses to glucose+GLP-1 and glucose+GLP-1+argi-
nine are governed by the same genetic factors as the
response to glucose alone. Although there is overlap in the
mechanism by which they stimulate insulin secretion, each
of these secretagogues also has a specific intracellular
pathway that may be influenced by different sets of genes
[18, 19].
Increased understanding of the genetics of the different
aspects of beta cell function and dysfunction may identify
new targets for glucose-lowering drugs or preventive
measures. The aim of this twin-family study was to explore
the heritability of beta cell insulin response by using a
modified hyperglycaemic clamp based on the procedure by
Fritsche and colleagues [21]. Apart from estimating the
heritability of insulin response to glucose (first and second
phase), GLP-1 and arginine, we also tested whether
different genetic factors influence insulin response to each
of these three secretagogues. Since the insulin response is
strongly correlated to BMI and insulin sensitivity [22, 23],
measures of BMI and insulin sensitivity were assessed on
the same day, the latter by the euglycaemic–hyperinsuli-
naemic clamp. This allowed us to test to which extent
genetic factors influencing insulin response overlap with
those influencing BMI and insulin sensitivity.
Methods
Design and participants This study used a twin/same-sex
sibling design to address the genetic and environmental
contribution to the variance of beta cell function in Dutch
twin families recruited from the Netherlands Twin Register
[24] as described previously [25]. The clamp tests were
performed in 125 (58 men) healthy participants, aged 20 to
50 years and of European origin. In the weeks prior to these
clamp tests, participants had been assessed with a 75 g
screening OGTT to exclude the presence of diabetes
mellitus. There were 34 monozygotic twin pairs and 13
same-sex dizygotic twin pairs from 47 families. Eight
monozygotic twin pairs and five dizygotic twin pairs had
one additional same-sex sibling. Two monozygotic twin
pairs had two additional same-sex siblings. In six more
families only one twin of the pair participated, together with
a same-sex sibling. In one family no twin pair but two
female siblings took part in the study. In total, 100 twins
and 25 siblings participated. Twin zygosity was determined
from DNA polymorphisms. In total 44 dizygotic/sibling
pairs could be formed. The median age difference between
twins and sibs was 3.5 years with a range of 1.8 to
9.1 years. Including an additional sibling in the classical
twin design significantly increases the power to detect the
genetic and environmental sources of variation [26].
All participants gave written informed consent. The
study was approved by the local Ethics Committee and
performed in accordance with the Declaration of Helsinki.
Euglycaemic–hyperinsulinaemic clamp After a 12 h fast
the clamp procedure [27] started in the clinic at 08:00
hours. Anthropometric measurements of weight (Seca
balance scale; Schinkel, Nieuwegein, the Netherlands),
height (Harpenden Stadiometer; Holtain, Crosswell, UK)
and waist and hip circumference [28] were performed. One
cannula was retrogradely placed in a heated dorsal hand
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vein to obtain arterialised blood. A second cannula was
inserted into the antecubital vein of the arm for infusion of
0.9% saline (wt/vol.), glucose 20% (wt/vol.) and insulin.
After baseline samples had been taken twice, a primed,
continuous (40 mU m−2min−1) insulin infusion (Actrapid;
Novo Nordisk, Bagsvaer, Denmark) was given for 120 min.
Glucose 20% was infused at a variable rate to maintain
blood glucose at 0.3 mmol/l below the fasting level and
within the range of 4.5 to 5.5 mmol/l. Blood glucose was
monitored at 5 min intervals; blood samples for hormonal
levels were obtained at 60, 90, 105 and 120 min.
Modified hyperglycaemic clamp At 1 h after completion of
the euglycaemic–hyperinsulinaemic clamp, the hypergly-
caemic clamp was performed at 10 mmol/l as described by
Fritsche et al. [21]. The blood glucose level was frequently
monitored (at least every 5 min) and the infusion rate of
glucose 20% accordingly adjusted. Blood samples for
measurement of insulin and C-peptide were drawn at fixed
time points, i.e. (1) at −5 and −2 min before the start of the
hyperglycaemic clamp; (2) every min for 10 min after a
bolus of each secretagogue; and (3) at 5 to 30 min intervals
in the periods in-between. At 0 min the participant received
an intravenous bolus of glucose for 1 min to acutely raise
glucose level to 10 mmol/l (bolus calculated as follows:
weight in kg×[10−prehyperglycaemic glucose level in
mmol/l]×27/200=ml glucose 20%). At 120 min (i.e. 2 h
later) GLP-1 (7-36 Amide Human; Polypeptide Laborato-
ries, Wolfenbuettel, Germany) was given as a bolus
injection (1.5 pmol/kg) for 1 min, followed by continuous
infusion of 0.5 pmol kg−1min−1. At 180 min, a bolus of 5 g
arginine was injected over 50 s on top of the GLP-1
infusion. The GLP-1 infusion was terminated 20 min after
the arginine bolus and the clamp finished.
Analytical procedures Blood glucose was assessed at
bedside using a glucose oxidase method (YSI 2300 Stat
plus; Yellow Springs Instruments, Yellow Springs, OH,
USA). This device has a within-run CVof 2% and a day-to-
day CV of 6% [29]. Blood for hormonal levels was
centrifuged (1,469 g) and the serum stored at −80°C. All
serum specimens were assessed for insulin and C-peptide
levels at the VU University Medical Centre (Department of
Clinical Chemistry, Amsterdam, the Netherlands) using an
immunometric assay luminescence method (ACS:Centaur;
Bayer Diagnostics, Mijdrecht, the Netherlands). There was no
cross-reactivity with proinsulin or split products. The inter
assay CV of insulin and C-peptide measurement was 6.5%
and 6% respectively. The intra-assay CV was 4% for both.
Calculations BMI was calculated as weight in kg/(height in
metres)2. The insulin sensitivity index (ISI) was defined as
the glucose infusion rate per kg of body weight during the
second h of the euglycaemic–hyperinsulinaemic clamp per
unit of serum insulin concentration (μmol kg−1min−1
(pmol/l)−1). The incremental insulin response to the
secretagogues was calculated in four periods named first-
phase, second-phase, GLP-1-stimulated insulin response
(GLP-1IR) and arginine-induced insulin response (ARG-
IR), using the AUCs of the measured insulin levels as
depicted in Fig. 1. The first phase comprised the acute
response to hyperglycaemia and was computed as the AUC
of the insulin level during min 1 to 10, using the mean
baseline level from −5 to −2 min. The second phase
comprised the AUC from 80 to 120 min, again using the
mean from −5 to −2 min as the baseline level. The GLP-
1IR was calculated as the AUC from 160 to 180 min, using
the last period of the second phase from 100 to 120 min as
the baseline. The acute ARG-IR was calculated as the AUC
from 182 to 185 min minus the prebolus level (at 180 min).
C-peptide responses to the three secretagogues were
calculated in the same way.
Statistical analyses All genetic analyses were carried out in
Mx [30], a structural equation modelling program specifi-
cally designed for the analysis of twin and family data. All
variables (BMI, ISI, first-phase, second-phase, GLP-1IR
and ARG-IR) were Z transformed prior to analysis (mean=0,
SD=1) to reduce the large differences in variances across the
variables. This transformation does not affect the estimates
of familial correlations or of heritabilities.
In a first step, we confirmed that the variances of the
variables were comparable for twins and siblings and that
the covariances between dizygotic twins could be equated
to those between a twin and a singleton sibling. The latter
allowed us to treat all sibling pairs sharing 50% of their
genetic material, whether dizygotic twin or twin-sibling
pair, in the same way. Next we estimated correlations
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Fig. 1 Insulin levels during the hyperglycaemic clamp. The curve
indicates the incremental insulin response to the different
secretagogues
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among family members and among variables in a model
that included the fixed effects of sex and age on each
variable. Broadly, we can distinguish between three types
of correlations: cross-variable within-person correlations
(phenotypic correlations), within-variable cross-person cor-
relations (familial correlations, i.e. monozygotic and dizy-
gotic/sibling correlations) and cross-variable cross-person
correlations. The phenotypic correlations describe the
correlations among the four secretory responses (first-
phase, second-phase, GLP-1IR and ARG-IR), BMI and
insulin sensitivity. The monozygotic and dizygotic/sibling
correlations describe the resemblance for these variables in
monozygotic twins and in all other pairs of first-degree
relatives (dizygotic twins, twin–sibling, sibling–sibling).
These correlations form the basis for estimating the relative
contributions of genetic and environmental factors to
individual differences in each variable. Monozygotic twin
pairs have all or nearly all genes in common; dizygotic twin
pairs, twin–sibling pairs and sibling–sibling pairs share on
average half of their segregating genes. If monozygotic
correlations are larger than the dizygotic/sibling correla-
tions, genetic influences are suggested.
Monozygotic and dizygotic/sibling correlations can also
be computed across variables (cross-variable cross-person
correlations), for example between the first-phase secretory
response of a twin and the second-phase secretory response of
his or her co-twin. When the cross-variable cross-person
correlation is larger in monozygotic twin than in dizygotic/
sibling pairs, this indicates that part of the association between
variables is explained by overlapping genetic factors.
Next, a multivariate genetic model [31] was fitted to the
data. For each of the six variables in the model, the total
variance was broken down into additive genetic variance
(A), common environmental variance shared by family
members (C) and unique environmental variance (E). The
full multivariate model included a set of six factors for A, C
and E (Electronic supplementary material [ESM] Fig. 1).
The first factor influences all six variables; the next factor
influences five variables and the last factor only one
variable. We tested whether the contributions of these A
and C factors were all significant using likelihood-ratio
tests. The difference in minus two times the log-likelihood
(−2LL) between two nested models has a χ2 distribution. A
corresponding p value >0.05 indicated that the more
parsimonious model did not fit the data less well than the
full model. Next the paths of each A and E factor to the six
variables were tested for significance. This procedure was
repeated to arrive at the most parsimonious model that
fitted the data. Under this model, we estimated the
heritability of each variable individually and broke this
heritability down into: (1) components that overlap with
BMI and ISI; (2) components that are specific to insulin
response but shared among secretagogues; and (3) compo-
nents that are specific to each secretagogue.
Results
Sample characteristics are shown in Table 1 and the insulin
levels attained during the hyperglycaemic clamp and GLP-1
Table 1 Sample characteristics
Variable Mean total SD Mean male SD Mean female SD
Number 125 58 67
Age (years) 30.8 5.6 30.4 5.2 31.2 5.9
Waist (cm) 85.5 10.2 88.2** 9.7 83.2 10.2
Weight (kg) 74.2 12.0 80.5** 10.4 68.8 10.5
BMI (kg/m2) 24.0 3.4 24.1 3.0 23.96 3.8
ISI (μmol min−1kg−1 [pmol/l]−1) 0.091 0.039 0.098 0.047 0.084 0.029
Insulin response (pmolxmin/l)a
First-phase 1,700 1,114 1,942* 1,247 1,484 938
Second-phase 9,337 7,471 10,830* 8,566 8,043 6,153
GLP-1 34,498 30,433 49,448** 35,333 21,361 16,829
Arginine 6,602 3,037 7,758** 3,147 5,554 2,533
C-peptide response (nmolxmin/l) a
First-phase 5.713 3.030 6.649** 3.383 4.878 2.409
Second-phase 66.68 26.65 74.74** 29.16 59.70 22.21
GLP-1 72.63 35.49 93.15** 36.05 54.60 23.20
Arginine 7.913 2.908 8.332 3.240 7.534 2.538
a Responses during the hyperglycaemic clamp are given as incremental responses, as defined in “Methods”
*p<0.05, **p<0.01 vs female
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and arginine additions in Fig. 1. The mean insulin secretion
in response to the secretagogues was larger in men. This
difference was highly significant after stimulation with GLP-1
(χ2=18.44, ∆df=1, p<0.001) and arginine (χ2=9.89,
∆df=1, p=0.002). The mean waist circumference was
significantly larger in men (χ2=7.05, ∆df=1, p=0.01). There
was no significant influence of age on the means of BMI,
ISI and the four secretory responses (χ2=11.03, ∆df=6,
p=0.09).
Phenotypic correlations are given in Table 2 and were all
significantly larger than zero. The insulin secretion in
response to glucose (first and second phase), glucose+
GLP-1 and glucose+GLP-1+arginine was highly correlated
(0.62<r<0.79).
Within-variable cross-person correlations are presented
in Table 3. Monozygotic twin correlations were all larger than
dizygotic twin/sibling correlations. This indicates that genetic
factors play a role in the variability of BMI, insulin sensitivity
and insulin secretion after intravenous administration of
glucose, glucose+GLP-1 and glucose+GLP-1+arginine.
Cross-variable cross-person correlations are shown in
Table 4. Monozygotic cross-twin cross-variable correlations
were all larger than the dizygotic twin/sibling cross-variable
correlations. These correlations indicate that overlapping
genes contribute to the phenotypic correlations between
BMI, insulin sensitivity and the insulin response to the
different secretagogues.
In the full multivariate genetic ACE model, the contri-
bution of A (combination of all additive genetic factors)
proved to be significant (χ2=48.77, ∆df=21, p=0.001),
while C (combination of all common environmental factors)
could be dropped from the model (χ2=4.77, ∆df=21,
p=1.00). Further testing showed that in the resulting AE
model, four single A paths and four single E paths could be
constrained to zero (χ2=6.64, ∆df=8, p=0.58). The most
parsimonious AE model with path loadings is presented in
ESM Fig. 2.
In this best-fitting model there are two sets of genetic
factors that influence the insulin response to the four
stimulations independently of BMI and ISI. The genetic
factors that influence BMI and ISI also influence the
variability of the four secretory responses. The heritability
estimates of the six variables are presented in Table 5. The
heritability of BMI is estimated at 74%. The heritability of
insulin sensitivity is 60%. Part of the genes influencing
BMI also influence ISI. The first-phase response has a
heritability of 52%, of which a small part (14%) is due to
genetic factors specific for the insulin response and
independent of the genetic factors for BMI and ISI
heritability. The second-phase response has a heritability
of 77%, of which nearly half can be attributed to the genes
specific for the insulin response. The heritability of insulin
secretion in response to GLP-1 was 53%, mainly deter-
mined by genes specific for the insulin response. The
secretory response to arginine had a heritability of 80%, of
which 44% reflects genetic overlap with BMI and ISI,
while 36% is specific for the insulin response. The
maximum insulin level during the test was generated
directly after the arginine bolus. The heritability of this
total peak level was 77%.
Three alternative analyses were performed to bolster our
confidence in these results (data not shown). First,
correlations in Tables 2, 3, 4 and 5 were recomputed using
C-peptide instead of insulin. This yielded virtually identical
results. Second, we used the total AUC with zero as a
baseline for the GLP-1 and arginine phases, rather than the
incremental AUC with the previous levels as a baseline. As
expected from the high correlation between absolute and
incremental GLP-1 (r=0.99) and arginine (r=0.91)
responses, highly similar patterns of twin sibling correla-
tions were obtained when using the total AUCs. Finally,
because waist circumference is seen by some researchers as
more discriminating for the risk of type 2 diabetes [32], we
repeated the analyses replacing BMI by waist. The
heritability for waist circumference was 75%, its correlation
to BMI r=0.84. Again highly comparable patterns of twin
sibling correlations were obtained when using waist
circumference instead of BMI.
Discussion
This study used a twin/sibling design to explore heritability
of the insulin response of the beta cell in healthy
Table 2 Phenotypic correlations (95% CI) between BMI, insulin sensitivity and the insulin responses of the beta cell
Variable BMI ISI First-phase Second-phase GLP-1IR
ISI −0.45 (−0.60, −0.24)
First-phase 0.42 (0.23, 0.58) −0.56 (−0.69, −0.40)
Second-phase 0.48 (0.30, 0.63) −0.57 (−0.69, −0.41) 0.79 (0.71, 0.86)
GLP-1IR 0.46 (0.27, 0.61) −0.56 (−0.69, −0.41) 0.67 (0.54, 0.76) 0.79 (0.71, 0.86)
ARG-IR 0.44 (0.26, 0.59) −0.55 (−0.68, −0.39) 0.62 (0.48, 0.73) 0.67 (0.54, 0.77) 0.70 (0.61, 0.80)
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individuals during a modified version of the hyperglycae-
mic clamp test used by Fritsche and colleagues [21]. The
heritability of first- and second-phase insulin secretion in
response to glucose was 52% and 77% respectively. For the
first phase our results fit neatly in the 35% to 76% range of
heritability estimates previously reported using the IVGTT
test [6, 11, 15–17]. However, previous heritability estimates
(28% and 58%) of second-phase insulin secretion in
response to IVGTT were considerably lower [11, 17] than
those found in our hyperglycaemic clamp. This may reflect
the greater precision inherent in the clamp method in
comparison to the IVGTT, but may also be due to the
different stimulation of the beta cell during the second
phase of both tests (maintaining 10 mmol/l glucose vs
decreasing glucose level).
Insulin secretion in response to administration of GLP-1
or GLP-1+arginine in the presence of hyperglycaemia has
been tentatively suggested as an endophenotype for type 2
diabetes mellitus risk [20]. Here we show for the first time
that these secretory responses do indeed show significant
heritability (GLP-1 53%, arginine 80%). Moreover, the
genetic information contained in the insulin response to
these two secretagogues is only partially captured by the
first-phase insulin response during the hyperglycaemic
clamp. The multivariate analysis of the insulin responses to
the three secretagogues and BMI and ISI showed that the
genetic variance unique to beta cell function (factors A3+A4)
contributed less strongly to individual differences in the
first-phase response (14%) than in the second-phase
response or in the responses to GLP-1 and GLP-1+arginine
(30–37%).
Overall, the findings clearly show that the genetic
variation in beta cell function is only partly attributable to
genes influencing BMI and ISI. These findings cannot
simply be attributed to a restricted range of BMI or ISI
values in this healthy sample, since our heritability
estimates of BMI and insulin sensitivity are very compara-
ble to previous estimates [11, 12, 33]. Furthermore, the
partial independence of genetic factors influencing beta cell
function from those influencing BMI is congruent with the
outcome of previous genome-wide association (GWA)
studies addressing the genetic risk of diabetes. These show
that correction for BMI can sometimes reduce the signif-
icance of SNP associations with type 2 diabetes, with the
FTO gene being the most prominent example [34]. This
suggests that obesity genes like FTO may belong to the first
genetic factor (A1) in ESM Fig. 2. This raises the question
of whether correction for BMI is appropriate if the goal is
to identify genes ‘that influence diabetes risk’. Part of the
genetic risk for insulin sensitivity and beta cell function
truly overlaps with the risk for obesity.
The partial independence of the genetic factors influenc-
ing the beta cell response from those influencing insulin
sensitivity is also congruent with the outcome of previous
GWA studies and the follow-up of their major candidate
genes in experimental studies. The majority of the ~20 loci
shown in GWA studies to be associated with type 2
diabetes or fasting glucose are almost all implicated in
Table 4 Cross-variable cross-person correlations (95% CI), with monozygotic twin-pairs in lower diagonal and dizygotic twin/sibling pairs in
upper diagonal
Variable BMI ISI First-phase Second-phase GLP-1IR ARG-IR
BMI −0.10
(−0.32, 0.12)
0.10
(−0.16, 0.33)
0.17
(−0.11, 0.40)
0.17
(−0.10, 0.40)
0.19
(−0.06, 0.41)
ISI −0.33
(−0.51, −0.18)
−0.25
(−0.46, −0.00)
−0.28
(−0.49, −0.02)
−0.20
(−0.42, 0.05)
−0.13
(−0.36, 0.11)
First-phase 0.31
(0.09, 0.50)
−0.43
(−0.60, −0.21)
0.27
(−0.12, 0.53)
0.24
(−0.11, 0.48)
0.14
(−0.17, 0.40)
Second-phase 0.33
(0.13, 0.51)
−0.45
(−0.61, −0.26)
0.60
(0.42, 0.72)
0.33
(−0.04, 0.59)
0.19
(−0.15, 0.45)
GLP-1IR 0.25
(0.03, 0.45)
−0.37
(−0.55, −0.14)
0.46
(0.25, 0.62)
0.56
(0.38, 0.70)
0.24
(−0.09, 0.49)
ARG-IR 0.34
(0.14, 0.51)
−0.46
(−0.61, −0.27)
0.46
(0.26, 0.61)
0.56
(0.40, 0.69)
0.52
(0.34, 0.66)
Table 3 Within-variable cross-person correlations (95% CI) for
monozygotic twin and dizygotic twin/sibling pairs
Variable Monozygotic
twin pairs
Dizygotic twin/
sibling pairs
BMI 0.75 (0.57, 0.83) 0.44 (0.17, 0.65)
ISI 0.76 (0.53, 0.87) 0.12 (−0.15, 0.38)
First-phase 0.63 (0.38, 0.78) 0.22 (−0.16, 0.51)
Second-phase 0.76 (0.61, 0.86) 0.31 (−0.12, 0.60)
GLP-1IR 0.57 (0.33, 0.74) 0.37 (−0.00, 0.67)
ARG-IR 0.82 (0.68, 0.89) 0.22 (−0.11, 0.50)
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defective beta cell function [14, 35]. Almost none of these
genes were found to affect peripheral insulin sensitivity.
Most notably, all previous studies that used a hyper-
glycaemic clamp procedure comparable to the one used
here confirm the independence of genetic effects on insulin
secretion and insulin sensitivity. For instance, the risk
variants of CDKAL1, IGF2BP2 [36], TCF7L2 [37] or
WFS1 [38] clearly impaired glucose- or GLP-1-induced
insulin secretion, but did not impact on insulin sensitivity.
It has often been suggested that beta cell dysfunction is
uncovered only when insulin resistance creates a strongly
increased insulin demand. This implies an interactive effect
between insulin resistance and beta cell function. In support
of such an effect it was recently shown that the summed
effects of the risk alleles in TCF7L2, CDKAL1, HHEX;
SLC30A8, IGF2BP2, CDKN2A/B, JAZF1 and WFS1 had a
stronger effect on beta cell function in participants with low
insulin sensitivity than in participants with high insulin
sensitivity [39]. Because we found that the genetic variation
in beta cell function is partly independent of the genetic
variation in ISI, the interactive effect between insulin
resistance and beta cell function could be partly due to
gene–gene interaction. Failing to account for such gene–
gene interactions may explain some of the missing
heritability plaguing GWA studies in diabetes [40].
In the near future, new candidate genes can be expected
to derive from the ongoing collaborative GWA studies on
diabetes or fasting glucose, which are still growing in scale.
We assert that functional annotation of these genes should
employ rigorous beta cell function tests including the
hyperglycaemic clamp procedure used here. For instance,
Schafer et al. [37], using a comparable hyperglycaemic
clamp+GLP-1+arginine as used in the current study,
showed that carriers of the risk allele in two variants
(rs7903146, rs12255372) of the TCF7L2 gene had un-
changed GLP-1 secretion, but significantly reduced GLP-1-
induced insulin secretion. This finding narrows the possible
role for TCF7L2 in type 2 diabetes, an often replicated
association, to a functional defect in GLP-1 in the beta
cells.
The major strength of our study, the clamp-based
measurement of insulin sensitivity and insulin responses
under a strict and uniform protocol, comes with a major
limitation. Due to the expensive, time-consuming and
demanding protocols, the sample was relatively small. This
is reflected in the fairly broad confidence intervals around
the estimates in Tables 2, 3, 4 and 5. As a consequence of
the modest sample size, the a priori power to detect
common environmental effects, for instance shared dietary
practices in childhood, or genetic non-additivity (domi-
nance, epistasis) was very poor [26]. Also, the two-factor
structure now found for beta cell responses might prove
more complex, i.e. with GLP1-specific and arginine-
specific genetic factors, when larger samples are assessed.
Further caution is needed in generalising these data beyond
the sample of relatively young, healthy Europeans used
here.
In conclusion, genetic factors explain most of the
individual differences in insulin response after administra-
tion of glucose and glucose combined with GLP-1 or GLP-1
+arginine in healthy adults. Our results show that the often
used first-phase response may give an incomplete picture of
the genes that are specific to beta cell function. They also
show that the genetic factors influencing beta cell function
are partly independent of the factors that influence BMI and
ISI, and that in genetic designs ‘correction’ for BMI and ISI
may not always be desirable. To chart the biological effects
of (new) candidate genes from GWA studies on type 2
diabetes, the hyperglycaemic GLP-1/arginine challenge test
may be a powerful tool.
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